Abstract:STXBP1-related disorders are among the most common genetic epilepsies and neurodevelopmental disorders. However, the longitudinal epilepsy course and developmental end points, have not yet been described in detail, which is a critical prerequisite for clinical trial readiness. Here, we assessed 1281 cumulative patient-years of seizure and developmental histories in 162 individuals with STXBP1-related disorders and established a natural history framework. STXBP1-related disorders are characterized by a dynamic pattern of seizures in the first year of life and high variability in neurodevelopmental trajectories in early childhood. Epilepsy onset differed across seizure types, with 90% cumulative onset for infantile spasms by 6 months and focal-onset seizures by 27 months of life. Epilepsy histories diverged between variant subgroups in the first 2 years of life, when individuals with protein-truncating variants and deletions in STXBP1 (n = 39) were more likely to have infantile spasms between 5 and 6 months followed by seizure remission, while individuals with missense variants (n = 30) had an increased risk for focal seizures and ongoing seizures after the first year. Developmental outcomes were mapped using milestone acquisition data in addition to standardized assessments including the Gross Motor Function Measure-66 Item Set and the Grasping and Visual-Motor Integration subsets of the Peabody Developmental Motor Scales. Quantification of end points revealed high variability during the first 5 years of life, with emerging stratification between clinical subgroups. An earlier epilepsy onset was associated with lower developmental abilities, most prominently when assessing gross motor development and expressive communication. We found that individuals with neonatal seizures or early infantile seizures followed by seizure offset by 12 months of life had more predictable seizure trajectories in early to late childhood compared to individuals with more severe seizure presentations, including individuals with refractory epilepsy throughout the first year. Characterization of anti-seizure medication response revealed age-dependent response over time, with phenobarbital, levetiracetam, topiramate and adrenocorticotropic hormone effective in reducing seizures in the first year of life, while clobazam and the ketogenic diet were effective in long-term seizure management. Virtual clinical trials using seizure frequency as the primary outcome resulted in wide range of trial success probabilities across the age span, with the highest probability in early childhood between 1 year and 3.5 years. In summary, we delineated epilepsy and developmental trajectories in STXBP1-related disorders using standardized measures, providing a foundation to interpret future therapeutic strategies and inform rational trial design.

Accelerating therapeutic development and clinical trial readiness for STXBP1 and SYNGAP1 disorders

424 Clinical Translational Approach to Targeted Therapy in SLC6A1-related Neurodevelopmental Disorder

GABAergic/glycinergic and glutamatergic neurons mediate distinct neurodevelopmental phenotypes of STXBP1 encephalopathy

STXBP1: fast-forward to a brighter future - a patient organization perspective

STXBP1 encephalopathies: Clinical spectrum, disease mechanisms, and therapeutic strategies

Delineating clinical and developmental outcomes in STXBP1-related disorders

Epilepsy Course and Developmental Trajectories in STXBP1-DEE

Assessing the Landscape of STXBP1-related Disorders in 534 Individuals

Altered synaptic connectivity in an in vitro human model of STXBP1 encephalopathy

Gene therapy for CNS disorders: modalities, delivery and translational challenges

Gene therapy for neurotransmitter‐related disorders

Bridging the translational gap: what can synaptopathies tell us about autism?

A Narrative Review on Molecular Mechanisms Involved

Hyperexcitability and translational phenotypes in a preclinical mouse model of SYNGAP1- related intellectual disability

The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives

Clinical Phenotype of a Rare Pathogenic Variant in STXBP1 Gene

Gene replacement therapies for inherited disorders of neurotransmission: Current progress in succinic semialdehyde dehydrogenase deficiency

Generation of humanized mouse models to support therapeutic development for SYNGAP1 and STXBP1 disorders

Genetic Advances in Neurodevelopmental Disorders

Nucleic Acid–Based Therapeutics in Orphan Neurological Disorders: Recent Developments

Impaired neuronal activity and differential gene expression in STXBP1 encephalopathy patient iPSC-derived GABAergic neurons